Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

Mark A. Socinski, Coleman Obasaju, David R Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz-Ares, Maurice Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. Spigel, Heather Wakelee, Nick Thatcher

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Squamous cell lung cancer (SqCLC) is a distinct histologic subtype of NSCLC that is challenging to treat because of specific clinicopathologic characteristics, which include older age, advanced disease at diagnosis, comorbid diseases, and the central location of tumors. These characteristics have a bearing on treatment outcomes in advanced SqCLC, resulting in a median survival approximately 30% shorter than for patients with other NSCLC subtypes. In the context of the specific features of SqCLC, we review challenges of treating SqCLC and the current guideline-recommended treatments for advanced (metastatic) SqCLC in different patient subpopulations. We also evaluate recently approved treatment options, including necitumumab, afatinib, nivolumab, pembrolizumab, and atezolizumab; discuss the survival benefits associated with each agent in the advanced SqCLC population; and propose a treatment algorithm incorporating these agents for this challenging-to-treat disease. Lastly, we review the preliminary clinical evidence for immunotherapy agents in development for advanced NSCLC.

Original languageEnglish (US)
Pages (from-to)165-183
Number of pages19
JournalJournal of Thoracic Oncology
Volume13
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Squamous Cell Neoplasms
Lung Neoplasms
Therapeutics
Survival
Immunotherapy
Guidelines
Population
Neoplasms

Keywords

  • Non–small cell lung cancer
  • Squamous cell lung cancer
  • Treatment algorithm
  • Treatment guidelines

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Socinski, M. A., Obasaju, C., Gandara, D. R., Hirsch, F. R., Bonomi, P., Bunn, P. A., ... Thatcher, N. (2018). Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. Journal of Thoracic Oncology, 13(2), 165-183. https://doi.org/10.1016/j.jtho.2017.11.111

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. / Socinski, Mark A.; Obasaju, Coleman; Gandara, David R; Hirsch, Fred R.; Bonomi, Philip; Bunn, Paul A.; Kim, Edward S.; Langer, Corey J.; Natale, Ronald B.; Novello, Silvia; Paz-Ares, Luis; Pérol, Maurice; Reck, Martin; Ramalingam, Suresh S.; Reynolds, Craig H.; Spigel, David R.; Wakelee, Heather; Thatcher, Nick.

In: Journal of Thoracic Oncology, Vol. 13, No. 2, 01.02.2018, p. 165-183.

Research output: Contribution to journalReview article

Socinski, MA, Obasaju, C, Gandara, DR, Hirsch, FR, Bonomi, P, Bunn, PA, Kim, ES, Langer, CJ, Natale, RB, Novello, S, Paz-Ares, L, Pérol, M, Reck, M, Ramalingam, SS, Reynolds, CH, Spigel, DR, Wakelee, H & Thatcher, N 2018, 'Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer', Journal of Thoracic Oncology, vol. 13, no. 2, pp. 165-183. https://doi.org/10.1016/j.jtho.2017.11.111
Socinski, Mark A. ; Obasaju, Coleman ; Gandara, David R ; Hirsch, Fred R. ; Bonomi, Philip ; Bunn, Paul A. ; Kim, Edward S. ; Langer, Corey J. ; Natale, Ronald B. ; Novello, Silvia ; Paz-Ares, Luis ; Pérol, Maurice ; Reck, Martin ; Ramalingam, Suresh S. ; Reynolds, Craig H. ; Spigel, David R. ; Wakelee, Heather ; Thatcher, Nick. / Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. In: Journal of Thoracic Oncology. 2018 ; Vol. 13, No. 2. pp. 165-183.
@article{078c5ecb2f474e698ea865c600ca3517,
title = "Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer",
abstract = "Squamous cell lung cancer (SqCLC) is a distinct histologic subtype of NSCLC that is challenging to treat because of specific clinicopathologic characteristics, which include older age, advanced disease at diagnosis, comorbid diseases, and the central location of tumors. These characteristics have a bearing on treatment outcomes in advanced SqCLC, resulting in a median survival approximately 30{\%} shorter than for patients with other NSCLC subtypes. In the context of the specific features of SqCLC, we review challenges of treating SqCLC and the current guideline-recommended treatments for advanced (metastatic) SqCLC in different patient subpopulations. We also evaluate recently approved treatment options, including necitumumab, afatinib, nivolumab, pembrolizumab, and atezolizumab; discuss the survival benefits associated with each agent in the advanced SqCLC population; and propose a treatment algorithm incorporating these agents for this challenging-to-treat disease. Lastly, we review the preliminary clinical evidence for immunotherapy agents in development for advanced NSCLC.",
keywords = "Non–small cell lung cancer, Squamous cell lung cancer, Treatment algorithm, Treatment guidelines",
author = "Socinski, {Mark A.} and Coleman Obasaju and Gandara, {David R} and Hirsch, {Fred R.} and Philip Bonomi and Bunn, {Paul A.} and Kim, {Edward S.} and Langer, {Corey J.} and Natale, {Ronald B.} and Silvia Novello and Luis Paz-Ares and Maurice P{\'e}rol and Martin Reck and Ramalingam, {Suresh S.} and Reynolds, {Craig H.} and Spigel, {David R.} and Heather Wakelee and Nick Thatcher",
year = "2018",
month = "2",
day = "1",
doi = "10.1016/j.jtho.2017.11.111",
language = "English (US)",
volume = "13",
pages = "165--183",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",
number = "2",

}

TY - JOUR

T1 - Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

AU - Socinski, Mark A.

AU - Obasaju, Coleman

AU - Gandara, David R

AU - Hirsch, Fred R.

AU - Bonomi, Philip

AU - Bunn, Paul A.

AU - Kim, Edward S.

AU - Langer, Corey J.

AU - Natale, Ronald B.

AU - Novello, Silvia

AU - Paz-Ares, Luis

AU - Pérol, Maurice

AU - Reck, Martin

AU - Ramalingam, Suresh S.

AU - Reynolds, Craig H.

AU - Spigel, David R.

AU - Wakelee, Heather

AU - Thatcher, Nick

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Squamous cell lung cancer (SqCLC) is a distinct histologic subtype of NSCLC that is challenging to treat because of specific clinicopathologic characteristics, which include older age, advanced disease at diagnosis, comorbid diseases, and the central location of tumors. These characteristics have a bearing on treatment outcomes in advanced SqCLC, resulting in a median survival approximately 30% shorter than for patients with other NSCLC subtypes. In the context of the specific features of SqCLC, we review challenges of treating SqCLC and the current guideline-recommended treatments for advanced (metastatic) SqCLC in different patient subpopulations. We also evaluate recently approved treatment options, including necitumumab, afatinib, nivolumab, pembrolizumab, and atezolizumab; discuss the survival benefits associated with each agent in the advanced SqCLC population; and propose a treatment algorithm incorporating these agents for this challenging-to-treat disease. Lastly, we review the preliminary clinical evidence for immunotherapy agents in development for advanced NSCLC.

AB - Squamous cell lung cancer (SqCLC) is a distinct histologic subtype of NSCLC that is challenging to treat because of specific clinicopathologic characteristics, which include older age, advanced disease at diagnosis, comorbid diseases, and the central location of tumors. These characteristics have a bearing on treatment outcomes in advanced SqCLC, resulting in a median survival approximately 30% shorter than for patients with other NSCLC subtypes. In the context of the specific features of SqCLC, we review challenges of treating SqCLC and the current guideline-recommended treatments for advanced (metastatic) SqCLC in different patient subpopulations. We also evaluate recently approved treatment options, including necitumumab, afatinib, nivolumab, pembrolizumab, and atezolizumab; discuss the survival benefits associated with each agent in the advanced SqCLC population; and propose a treatment algorithm incorporating these agents for this challenging-to-treat disease. Lastly, we review the preliminary clinical evidence for immunotherapy agents in development for advanced NSCLC.

KW - Non–small cell lung cancer

KW - Squamous cell lung cancer

KW - Treatment algorithm

KW - Treatment guidelines

UR - http://www.scopus.com/inward/record.url?scp=85042408205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042408205&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2017.11.111

DO - 10.1016/j.jtho.2017.11.111

M3 - Review article

C2 - 29175116

AN - SCOPUS:85042408205

VL - 13

SP - 165

EP - 183

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

IS - 2

ER -